Management of cancer therapy-induced oral mucositis
Article first published online: 12 SEP 2011
© 2011 Wiley Periodicals, Inc.
Volume 24, Issue 4, pages 424–431, July/August 2011
How to Cite
BARASCH, A. and EPSTEIN, J. B. (2011), Management of cancer therapy-induced oral mucositis. Dermatologic Therapy, 24: 424–431. doi: 10.1111/j.1529-8019.2011.01434.x
- Issue published online: 12 SEP 2011
- Article first published online: 12 SEP 2011
The oral mucosa is a common site for collateral damage of cancer therapies, including radiation, cytotoxic medication, and newer targeted therapies. Ulcerative oral mucositis is typically painful and affects oral functions including speech, and oral intake of food and medications, thus impacting the quality of life. Denuded epithelium may also provide access of oral microbial flora to the deeper tissues and the circulation. Prevention of oral mucositis is an ongoing quest currently with relatively few answers. In this chapter, the present authors discuss the evidence and current practice for prophylaxis and management of this treatment side effect in cancer patients.